<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05078346</url>
  </required_header>
  <id_info>
    <org_study_id>2024_NR</org_study_id>
    <nct_id>NCT05078346</nct_id>
  </id_info>
  <brief_title>Immune Fitness Prediction</brief_title>
  <official_title>Observational Study to Determine the Association Between Self-rated, Perceived Immune Fitness (Using Questionnaire) With Biological Assessment of Immune Fitness (Immune Signatures in the Blood).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nestlé</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nestlé</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall objective of the study is to determine whether self-rated, perceived immune&#xD;
      fitness (using questionnaire) is associated with biological assessment of immune fitness&#xD;
      (immune signatures in the blood).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 2, 2021</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of different immune cell types in whole blood</measure>
    <time_frame>6 - 12 months after the start of the trial</time_frame>
    <description>Immune cell type profiling in whole blood by mass cytometry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Relative quantification of immune protein in plasma</measure>
    <time_frame>6 - 12 months after the start of the trial</time_frame>
    <description>Proteomic analysis in plasma by proximity extension assay</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Amount of cytokines expressed by peripheral blood mononuclear cells</measure>
    <time_frame>6 - 12 months after the start of the trial</time_frame>
    <description>Cytokine quantification by proximity extension assay</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Amount of analytes in serum</measure>
    <time_frame>6 - 12 months after the start of the trial</time_frame>
    <description>Blood chemistry</description>
  </primary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Healthy Adults</condition>
  <biospec_retention>None Retained</biospec_retention>
  <biospec_descr>
    <textblock>
      blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Healthy adults&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Ability to understand and sign the informed consent&#xD;
&#xD;
          2. Healthy adult men and/or women, 35-65 years old&#xD;
&#xD;
          3. BMI &gt;18 and &lt;30 kg/m2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Volunteer who cannot be expected to comply with the protocol&#xD;
&#xD;
          2. Individuals with self-reported chronic disease; or who have any clinical condition&#xD;
             which the investigator deems relevant for exclusion from the study,&#xD;
&#xD;
          3. Individuals with an impaired immune system that may confound immune response testing;&#xD;
             i.e. any condition that impairs participant immune response through either the&#xD;
             condition itself or through the treatment of the condition,&#xD;
&#xD;
          4. Family or hierarchical relationships with Clinical Innovation Lab at Nestlé Research,&#xD;
             Lausanne, Switzerland&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mario Noti, PhD</last_name>
    <phone>+41 21 785-9474</phone>
    <phone_ext>9474</phone_ext>
    <email>mario.noti@rd.nestle.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Nestlé Clinical Research Unit</name>
      <address>
        <city>Lausanne</city>
        <state>Vaud</state>
        <zip>1000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nathalie Piccardi</last_name>
      <phone>021 785 95 10</phone>
      <phone_ext>9510</phone_ext>
      <email>nathalie.piccardi@rdls.nestle.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 26, 2021</study_first_submitted>
  <study_first_submitted_qc>September 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 14, 2021</study_first_posted>
  <last_update_submitted>September 30, 2021</last_update_submitted>
  <last_update_submitted_qc>September 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

